[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhujiang Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":637},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,64,0,25,[9,47,78,107,137,168,192,213,234,253,268,296,324,349,373,394,419,440,462,487,507,532,551,581,614],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100622168","phase-4-anrikefon-vs-nalfurafine-for-sleep-quality-in-hemodialysis-patients-with-ckd-ap-100622168",false,"NCT07380113","Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP","An Exploratory Study Comparing Anrikefon With Nalfurafine in Improving Sleep Quality Among CKD-aP Patients Undergoing Hemodialysis: An Open-Label Randomized Controlled Clinical Trial","Anrikefon","Inclusion Criteria:\n\n1. Be able to understand the procedures and methods of this trial, be willing to strictly follow the clinical research protocol to complete this trial, and voluntarily sign the informed consent form.\n2. Male or female individuals aged 18 or above and 75 or above.\n3. Patients with end-stage renal disease received regular hemodialysis three times a week before the screening period (whether they met the requirements for regular dialysis was determined based on the opinions of the researchers).\n4. Meet the diagnostic criteria for chronic kidney disease-associated pruritus (CKD-aP).\n\n   1. Patients with chronic kidney disease (CKD) presenting with pruritus, with other identifiable causes of pruritus excluded.\n   2. Pruritus occurring on at least 3 days within a 2-week period, with multiple episodes per day, each lasting for several minutes, and having an impact on the patient's daily life.\n   3. Recurrent pruritus persisting for at least 6 weeks.A diagnosis requires that all three criteria above be met simultaneously.\n5. The subjects were evaluated using the Worst Itch Numerical Rating Scale (WI-NRS) for the most severe pruritus intensity and met the baseline pruritus intensity of ≥ 4 points.\n6. The subjects have completed the Pittsburgh Sleep Quality Index (PSQI) assessment during the screening period and met the baseline PSQI score \\> 7 points.\n\nExclusion Criteria:\n\n1. Participants with other serious systemic diseases that may affect their ability to participate in the study, as assessed by the investigator, including but not limited to:\n\n   1. Severe cardiovascular diseases, such as unstable angina, myocardial infarction, severe arrhythmias, World Health Organization (WHO) heart function classification III-IV during screening, poorly controlled hypertension or hypotension despite active treatment, and recurrent asthma.\n   2. A history of cerebrovascular accident (CVA) within the last 6 months.\n   3. Malignant tumors, excluding those that are curable, such as cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma of the skin, or any other cancer that has been cured (with no evidence of disease recurrence for 5 years).\n2. It is expected to undergo kidney transplantation and\u002For parathyroidectomy during the study period.\n3. The subjects are currently undergoing ultraviolet B treatment or are expected to receive such treatment during the study period.\n4. Have participated in any clinical trials of other drugs or medical devices within one month prior to screening (treatment with drugs or medical devices that have received clinical trials).\n5. Patients who have used the following drugs within 7 days before screening:\n\n   1. those who have used opioids.\n   2. those who must use opioids other than the investigational drug during the study period.\n   3. those who has used gabapentin, pregabalin and calcineurin inhibitors;\n   4. those who use drugs that can affect the efficacy judgment of anti-itching, including but not limited to antipsychotic drugs, sedative-hypnotic drugs, selective serotonin reuptake inhibitors (SSRIs), anti-anxiety drugs, or tricyclic antidepressants.\n6. After screening and enrollment, new antihistamines (such as antihistamines and corticosteroids, etc. (oral, intravenous or topical)) were prescribed, or the types, dosages or frequencies of these drugs were changed.\n7. Patients who have used any hypnotic or sedative medications (including benzodiazepine hypnotics, non-benzodiazepine hypnotics, melatonin receptor agonists, etc.) within 1 month prior to the screening period and baseline assessment.\n8. There is a history of allergy to opioid drugs, or it is known that there is a history of allergy to investigatory drugs or components of remedial drugs or other drugs or excipients with similar chemical structures.\n9. Severe hematological and liver function abnormalities during screening, meeting any one of the following clinical laboratory test results:\n\n   1. Hematology: Hemoglobin \\\u003C 80g\u002FL.\n   2. Liver function:\n\n      * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2.5× upper limit of normal (ULN).\n      * Total bilirubin (TBIL) \\> 2×ULN.\n10. Subjects who had any active infections during screening and whom the researchers considered unsuitable for inclusion (including but not limited to acute hepatitis, skin infections, etc.).\n11. As determined by the researchers, any other physical or mental illness or condition that may increase the risk of the trial, affect the subjects' compliance with the protocol, or affect the subjects' completion of the trial.","ALL","18 Years","75 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","The goal of this clinical trial is to compare a new intravenous drug, Anruikefen, with a traditional oral medication, nalfurafine orally disintegrating tablets, in improving sleep quality in patients with chronic kidney disease-associated pruritus. Sleep quality will be primarily assessed using the Pittsburgh Sleep Quality Index (PSQI). The study will also evaluate the safety of Anruikefen.\n\nThe main questions it aims to answer are:\n\n* Does Anruikefen injection improve sleep quality better than oral nalfurafine?\n* Does Anruikefen injection improve patients' quality of life more than oral nalfurafine? Researchers will compare Anruikefen with nalfurafine (an active control drug) to evaluate differences in their effects on sleep quality in patients with chronic kidney disease-associated pruritus.\n\nParticipants will:\n\n* Receive either Anruikefen injection (0.3 μg\u002Fkg, three times per week) or nalfurafine hydrochloride orally disintegrating tablets (2.5 μg once daily).\n* Continue treatment for 4 weeks, followed by a 1-week safety follow-up.\n* Complete the Pittsburgh Sleep Quality Index and other quality-of-life questionnaires after one month.",[29,30,31,32,33,34],"Pruritus Chronic","Kidney Diseases, Chronic","Renal Insufficiency, Chronic","Uremia; Chronic","Pruritus Due to Systemic Disorder (Disorder)","Pruritus Due to Hemodialysis","NOT_YET_RECRUITING","2026-06-14",{"date":38,"type":39},"2026-06-16","ACTUAL",{"date":41,"type":23},"2026-07-01",{"date":43,"type":23},"2027-12-31",{"name":45,"class":46},"Zhujiang Hospital","OTHER",{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100638273","ai-driven-metabolic-cohort-in-overweightobese-chinese-adults-100638273","NCT07584330","AI-Driven Metabolic Cohort in Overweight\u002FObese Chinese Adults","Chinese Overweight\u002FObese - Diabetes Metabolic Spectrum Cohort: An Artificial Intelligence-Driven Prospective Study","COMET-AI","Inclusion Criteria:\n\n1. Able to understand and voluntarily sign the informed consent form, and willing to comply with all study requirements.\n2. Age between 18 and 60 years (inclusive).\n3. Meets at least one of the following overweight\u002Fobesity criteria: a) BMI ≥ 24 kg\u002Fm²; b) male waist circumference ≥ 90 cm, female waist circumference ≥ 85 cm.\n4. Capable of basic smartphone operation and able to use WeChat or similar communication tools for daily communication.\n\nExclusion Criteria:\n\n1. Diagnosis of type 1 diabetes, latent autoimmune diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), or other specific types of diabetes.\n2. Endocrine or metabolic diseases that may affect body weight, including untreated thyroid disorders (hyperthyroidism: TSH \\\u003C 0.1 mIU\u002FL with FT4 \\> upper normal limit; hypothyroidism: TSH \\> 10 mIU\u002FL), Cushing syndrome, acromegaly, polycystic ovary syndrome, or hypopituitarism.\n3. Severe liver disease (Child-Pugh class B or C).\n4. Renal insufficiency (estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n5. Severe cardiac dysfunction (New York Heart Association class III or IV).\n6. Major cardiovascular or cerebrovascular event within the past 3 months (acute coronary syndrome, stroke).\n7. Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic ≥ 110 mmHg) or uncontrolled diabetes (HbA1c ≥ 9.0%).\n8. Active malignancy (diagnosed or treated within the last 3 years).\n9. Inflammatory bowel disease or conditions causing malabsorption (Crohn disease, active ulcerative colitis, pancreatitis with steatorrhea).\n10. Neuropsychiatric disorders (anorexia nervosa, bulimia nervosa, schizophrenia, major depression, or bipolar disorder).\n11. Diseases or physical conditions that impair motor function (severe osteoarthritis, Parkinson disease, paralysis, or cardiopulmonary insufficiency).\n12. Long-term use of antipsychotic drugs, systemic glucocorticoids, or other medications judged by the investigator to affect study outcomes.\n13. Pregnancy or planned pregnancy during the study period.\n14. History of or planned organ transplantation.\n15. Inability to operate the AI-based system or comply with follow-up procedures.\n16. Concurrent participation in another interventional clinical trial that may influence the results of this study.\n17. Unwilling or unable to provide informed consent.","60 Years",{"count":57,"type":23},2800,"OBSERVATIONAL","The goal of this observational cohort study is to delineate the five-year dynamic trajectories of metabolic phenotypes in Chinese adults with overweight or obesity, with or without type 2 diabetes, focusing on transition rates from metabolically healthy overweight\u002Fobesity to unhealthy overweight\u002Fobesity or to type 2 diabetes, as well as the incidence and progression of diabetic complications and cardiovascular events in those with type 2 diabetes and overweight\u002Fobesity. Researchers will compare three phenotype groups, namely metabolically healthy overweight\u002Fobesity, metabolically unhealthy overweight\u002Fobesity, and type 2 diabetes with overweight\u002Fobesity, to assess differences in metabolic parameter changes, complication rates, and cardiovascular risk. Participants will use a digital health management platform for data upload and lifestyle support, and will complete comprehensive health assessments at baseline, at 2.5 years, and at 5 years, along with annual light follow-ups.",[61,62,63,64],"Overweight and Obesity","Diabetes Mellitus, Type 2","Prediabetic State","Metabolic Syndrome",[61,66,64,67,68,69],"Type 2 Diabetes Mellitus","Metabolic Phenotype","Prospective Study","Cohort Study","2026-05-07",{"date":72,"type":39},"2026-05-13",{"date":74,"type":23},"2026-05-01",{"date":76,"type":23},"2032-04-01",{"name":45,"class":46},{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":24,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":105,"locationsCount":106},"100451629","effect-of-remimazolam-with-protocolized-sedation-on-critical-ill-mechanical-ventilated-patients-compared-with-midazolam-100451629","NCT05160987","Effect of Remimazolam With Protocolized Sedation on Critical Ill, Mechanical Ventilated Patients Compared With Midazolam","Effect of Remimazolam With Protocolized Sedation on Critical Ill, Mechanical Ventilated Patients Compared With Midazolam - A Parallel, Multicenter, Single-blind Randomized Controlled Trial","Inclusion Criteria:\n\n1. Critical ill patients that are mechanically ventilated within the first 48h of admission to the ICU and who would remain in the ICU for over 72h were enrolled in this study.\n2. Age 18-80 years.\n3. Voluntary informed consent.\n\nExclusion Criteria:\n\n1. Surgical treatment is performed within 24 hours.\n2. Craniocerebral injury, post neurosurgery, non drug coma, mental illness or peripheral neuropathy.\n3. Heart rates are less than 50 beats \u002F min or severe atrioventricular block without pacemaker support.\n4. The mean arterial pressure is less than 55 mmHg even though fluids and vasoactive drugs are administrated.\n5. Patients who are known or suspected allergy to benzodiazepines, propofol, dexmedetomidine or opioids.\n6. History of alcohol and drug abuse.\n7. End stages of lung diseases, such as pulmonary fibrosis, lung damage, etc.\n8. Pregnancy.","80 Years",{"count":87,"type":23},440,[89],"NA","In this parallel, multicenter, single-blind randomized controlled trial, mechanical ventilated patients will be randomly assigned to two groups. One receives remimazolam to achieve sedation goals, while the other receives Midazolam. The primary outcome is the effect of remimazolam on duration of mechanical ventilated of critical patients compared to midazolam.",[92],"Sedation and Analgesia",[94,95,96,97],"Remimazolam","Midazolam","duration of mechanical ventilation","Sedation","RECRUITING","2026-04-15",{"date":101,"type":39},"2026-04-17",{"date":103,"type":39},"2022-03-29",{"date":43,"type":23},{"name":45,"class":46},1,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":115,"targetDuration":4,"studyType":24,"phases":117,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":106},"100634003","phase-2-phase-ii-clinical-study-of-probiotic-lr607-in-patients-with-non-small-cell-lung-cancer-100634003","NCT07534033","Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer","Probiotics With High Expression of DL-peptidase (LR607) Can Enhance the Efficacy of Chemoradiotherapy in Resectable Stage IIB-IIIB Non-small Cell Lung Cancer: a Single-arm, Open-label, Multicenter, Phase II Clinical Trial","Inclusion Criteria:\n\n1. Histologically confirmed newly diagnosed patients\n2. ECOG performance status 0-1\n3. Age ≥18 years\n4. Measurable lesions (RECIST v1.1)\n5. Organ function meeting the requirements for chemotherapy and immunotherapy.\n\nExclusion Criteria:\n\n1. Including active autoimmune diseases\n2. Recent use of immunosuppressants\n3. Interstitial lung disease\n4. Presence of other malignancies\n5. History of immunotherapy\n6. Active infection\n7. Pregnancy or drug allergies",true,{"count":116,"type":23},46,[118],"PHASE2","The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include:\n\nCan LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 combined with neoadjuvant chemoimmunotherapy and treatment-related adverse reactions? What changes occur in the gut microbiota composition at the species level and gut metabolites of subjects after LR607 treatment?\n\nParticipants will:\n\nTake LR607 daily for 3 months Visit the hospital for check-ups and examinations every month Record their pathological response, tumor recurrence, and treatment-related adverse reactions",[121,122,123,124],"NSCLC Diagnosed by Histology or Cytology","A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection","Overall Lung Function is Adequate for the Planned Lung Resection","AJCC is Classified as IB-IIIC",[126,127,128],"NSCLC","IB-IIIC stage","Resectable NSCLC","2026-04-13",{"date":131,"type":39},"2026-04-16",{"date":133,"type":39},"2025-12-06",{"date":135,"type":23},"2027-12-23",{"name":45,"class":46},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":24,"phases":147,"briefSummary":148,"conditions":149,"keywords":153,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":106},"100634442","effectiveness-of-ttis-for-improving-consciousness-in-patients-with-doc-100634442","NCT07539740","Effectiveness of tTIs for Improving Consciousness in Patients With DoC","Effectiveness of Theta-Burst Patterned Temporal Interference Stimulation for Improving Awareness in Patients With Disorders of Consciousness: A Multicenter Randomized Double-Blind Controlled Trial","Inclusion Criteria:\n\n* Age: 18 to 70 years old.\n* Condition: Patients diagnosed with Disorders of Consciousness (DoC), including Vegetative State (VS)\u002FUnresponsive Wakefulness Syndrome (UWS) or Minimally Conscious State (MCS) according to international guidelines.\n* Duration: Disease course ≤ 1 year.Medical History: No history of neuro-psychiatric disorders prior to the brain injury.\n* Handedness: Right-handed.Safety: No contraindications for tTIs, EEG, or MRI.\n* Medication: Not currently using sedative drugs or medications that interfere with brain stimulation, such as Na2+ or Ca2+ channel blockers, or NMDA receptor antagonists.\n\nExclusion Criteria:\n\n* Concurrent Trials: Participation in other non-invasive or invasive neuromodulation trials.\n* Epilepsy: Uncontrolled epilepsy, defined as a seizure within 4 weeks prior to enrollment.\n* Implants: Presence of metal implants in the skull, brain pacemakers, or implanted brain devices (e.g., spinal cord stimulator).\n* Structural Issues: Skull defects at the site of stimulation that prevent the implementation of tTIs.\n* Systemic Implants: Presence of systemic metal implants, such as cardiac pacemakers.","70 Years",{"count":146,"type":23},136,[89],"The goal of this clinical trial is to learn if a new type of brain stimulation called theta-burst patterned temporal interference stimulation (tTIs) works to improve awareness in people with disorders of consciousness (DoC). The main questions it aims to answer are:\n\n1. Does tTIs help people with disorders of consciousness show more signs of awareness?\n2. Does tTIs improve the brain's ability to process information and connect different brain areas? Is tTIs safe and easy for people with disorders of consciousness to tolerate? Researchers will compare a group receiving active tTIs to a group receiving a \"sham\" stimulation (a look-alike stimulation that delivers no real current) to see if the real stimulation works better.\n\nParticipants will:Receive either active tTIs or sham stimulation twice a day for 5 consecutive days (total of 10 sessions). Undergo brain activity tests (EEG) and physical exams to check their level of awareness before and after the 5 days of treatment. Have their progress followed by researchers through phone calls at 1, 3, and 6 months after the treatment ends.",[150,151,152],"Disorders of Consciousness","Vegetative State","Minimally Conscious State",[154,155,156,157,158,159,160],"Temporal Interference Stimulation (tTIs)","Theta-burst Patterned Stimulation","Deep Brain Stimulation (Non-invasive)","Thalamic Stimulation","Centromedian-parafascicular Nuclei (CM-pf)","Perturbational Complexity Index (PCI)","Coma Recovery Scale-Revised (CRS-R)",{"date":162,"type":39},"2026-04-20",{"date":164,"type":39},"2026-03-08",{"date":166,"type":23},"2028-05-31",{"name":45,"class":46},{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":175,"targetDuration":4,"studyType":24,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":106},"100629009","phase-2-comparison-of-anticoagulant-effects-of-different-doses-of-nafamostat-in-continuous-renal-replacement-therapy-crrt-in-the-intensive-care-unit-icu-100629009","NCT07469072","Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU)","Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU): A Single-Center, Randomized, Open-Label, Parallel-Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age \\& Gender: Aged 18 to 80 years, regardless of gender.\n2. Clinical Indication: Admitted to the Intensive Care Unit (ICU) with a confirmed indication for Continuous Renal Replacement Therapy (CRRT) and an expected treatment duration of greater than 24 hours.\n3. Coagulation Status: Normal coagulation function prior to CRRT initiation, defined as:International Normalized Ratio (INR) ≤ 1.5,Fibrinogen (FIB) ≥ 1.5 g\u002FL,Activated Partial Thromboplastin Time (APTT) ≤ 45 seconds\n4. Platelet Count: Platelet count (PLT) ≥ 50 × 10⁹\u002FL.\n5. Body Mass Index (BMI): 18.5 kg\u002Fm² ≤ BMI ≤ 25 kg\u002Fm².\n6. Informed Consent: Written informed consent obtained from the patient or their legally authorized representative.\n\nExclusion Criteria:\n\n1. Hypersensitivity: Known allergy or hypersensitivity to Nafamostat Mesilate or any component of the formulation.\n2. Active Bleeding: Presence of active bleeding or a high risk of bleeding that contraindicates anticoagulation (e.g., active gastrointestinal bleeding, intracranial hemorrhage, or recent major surgery with a high bleeding risk).\n3. Pregnancy\u002FLactation: Pregnant or breastfeeding women.\n4. Concurrent Anticoagulation: Current use of other systemic anticoagulants (e.g., unfractionated heparin, low molecular weight heparin, warfarin, or direct oral anticoagulants) that cannot be discontinued.\n5. Concurrent Extracorporeal Support: Concurrent use of other extracorporeal life support or blood purification therapies that may interfere with coagulation assessment, such as Extracorporeal Membrane Oxygenation (ECMO), Intra-Aortic Balloon Pump (IABP), or Plasma Exchange (PE).\n6. Severe Liver Dysfunction: Severe hepatic impairment (Child-Pugh Class C) or baseline total bilirubin levels exceeding 5 times the upper limit of normal.\n7. Limited Life Expectancy: Expected survival time of less than 24 hours due to the progression of underlying disease.\n8. Conflicting Trials: Current participation in another interventional clinical trial that may influence the outcomes of this study.",{"count":176,"type":23},92,[118],"This is a single-center, randomized, open-label, parallel-controlled clinical trial designed to investigate the anticoagulation efficacy and safety of different initial doses of Nafamostat Mesilate (NM) in ICU patients undergoing Continuous Renal Replacement Therapy (CRRT). Researchers will screen patients admitted to the Department of Critical Care Medicine at Zhujiang Hospital, Southern Medical University, to identify eligible participants based on inclusion and exclusion criteria. After obtaining informed consent, participants will be randomized into two groups.\n\nOn the basis of standardized CRRT treatment, the Low-Dose Group (Group A) will receive a continuous infusion of Nafamostat Mesilate at an initial dose of 20 mg\u002Fh, while the High-Dose Group (Group B) will receive an initial dose of 50 mg\u002Fh. The drug will be continuously infused pre-filter into the CRRT circuit. Dosage adjustments will be made for both groups to maintain target anticoagulation levels while ensuring that pre-filter safety limits are not exceeded. The primary outcome measure is filter lifespan, along with other secondary outcomes.",[180],"Continuous Renal Replacement Therapy (CRRT)",[180,182,183],"Anticoagulation Efficacy","Nafamostat Mesilate (NM)","2026-04-09",{"date":186,"type":39},"2026-04-14",{"date":188,"type":39},"2026-04-07",{"date":190,"type":23},"2027-06-30",{"name":45,"class":46},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":144,"enrollmentInfo":200,"targetDuration":4,"studyType":24,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":106},"100614833","effect-of-transcutaneous-auricular-vagus-nerve-stimulation-on-patients-with-disorders-of-consciousness-100614833","NCT07284732","Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Patients With Disorders of Consciousness","Effects of Pairing Transcutaneous Auricular Vagus Nerve Stimulation on Patients With Disorders of Consciousness: An Exploratory Single-Center Randomized Controlled Trial","taVNS","Inclusion Criteria:\n\n* Aged 18-70 years, with a disease duration exceeding 28 days but not longer than 1 year.\n* Patients diagnosed with disorders of consciousness (DoC), specifically classified as either vegetative state (VS) or minimally conscious state (MCS) according to the Coma Recovery Scale-Revised (CRS-R) based on international guidelines.\n* No prior history of neuropsychiatric disorders.\n* Absence of contraindications to transcutaneous auricular vagus nerve stimulation (taVNS) or electroencephalography (EEG), and no concurrent use of sedatives or medications that may interfere with cerebral stimulation-including Na⁺ or Ca²⁺ channel blockers or NMDA receptor antagonists.\n* Intact skin at the auricular site.\n\nExclusion Criteria:\n\n* Participation in other trials involving non-invasive or invasive neuromodulation.\n* Uncontrolled epilepsy, defined as seizures occurring within 4 weeks prior to enrollment.\n* Presence of cranial metal implants, pacemakers, craniotomy at the stimulation site, implanted brain devices, or similar conditions.\n* Cardiac arrhythmia or other significant cardiovascular abnormalities;\n* History of respiratory disorders, including dyspnea, asthma, or hyperventilation.\n* History of vasovagal syncope.",{"count":201,"type":23},20,[89],"Consciousness disorders following severe brain injury refer to a series of disturbances in arousal and cognition secondary to organic brain diseases, including Unresponsive Wakefulness Syndrome (UWS) (also termed Vegetative State, VS) and Minimally Conscious State (MCS). Disorders of consciousness(DoC) is listed in the International Statistical Classification of Diseases and Related Health Problems, though it is not currently recognized as an independent and consistent diagnostic category. According to epidemiological surveys, conservative estimates suggest that 70,000 to 100,000 new cases of DoC are reported annually in China, posing significant challenges for clinical diagnosis and treatment. Accurately assessing DoC, understanding its neurobiological underpinnings, and developing effective rehabilitation strategies remain subjects requiring further investigation through both clinical and basic neuroscience research.\n\nTranscutaneous Auricular Vagus Nerve Stimulation (taVNS) is a non-invasive brain stimulation technique that delivers electrical impulses to the auricular branch of the vagus nerve. Substantial evidence indicates that taVNS serves as a therapeutic intervention for various neurological and psychiatric disorders, such as epilepsy, treatment-resistant depression, migraines, and cognitive impairments. As an emerging neurostimulation technique, taVNS has been investigated for its potential to promote the recovery of awareness in patients with DoC. However, clinical evidence remains limited, underscoring the need for further trials to substantiate its efficacy. Developed from traditional implanted Vagus Nerve Stimulation(VNS), taVNS offers high safety and minimal to negligible side effects, presenting a promising therapeutic avenue for patients with severe traumatic brain injury and disorders of consciousness.\n\nMethods: This study is a single-arm trial. A total of 20 patients are planned to be enrolled. Each patient will receive taVNS twice daily over a period of 10 consecutive days, totaling 20 sessions. Primary and secondary outcome measures will be assessed at baseline and after the completion of taVNS treatment. The primary efficacy endpoint will be the change in behavioral responses as evaluated by the Coma Recovery Scale-Revised (CRS-R). Additionally, resting-state high-density electroencephalography (EEG) and combined transcranial magnetic stimulation with EEG (TMS-EEG) recordings will be utilized to investigate the neurophysiological correlates of taVNS intervention.\n\nDiscussion: This study will provide valuable insights to inform the selection of treatment approaches for patients with disorders of consciousness. By employing a pre-post within-subject comparison design, it aims to validate the therapeutic role of Closed-Loop Transcutaneous Auricular Vagus Nerve Stimulation (CL-taVNS) in this patient population.",[150],"2026-03-25",{"date":207,"type":39},"2026-03-31",{"date":209,"type":39},"2024-05-01",{"date":211,"type":23},"2027-05-31",{"name":45,"class":46},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":220,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":233},"100528153","prediction-of-hepatocellular-carcinoma-recurrence-after-curative-treatment-by-longitudinal-monitoring-mrd-based-on-ctdna-100528153","NCT06157060","Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA","Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring Minimal Residual Disease Based on Circulating Tumor DNA","Inclusion Criteria:\n\n1. Male or female patients aged 18-75 years;\n2. Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0 \u002F stage A\u002Fstage B, eligible for radical surgery;\n3. ECOG physical status score is 0-1;\n4. Child-Pugh score is 5-6 points (Level A);\n5. Not received any anti-tumor therapy;\n6. Laboratory tests were at normal levels within 7 days before enrollment.\n\nExclusion Criteria:\n\n1. Patient can't provide blood samples for ctDNA testing;\n2. Patient with two or more types of tumors at the same time;\n3. Non-primary liver lesions;\n4. Pregnant or lactating women;\n5. Patient with a history of other malignant tumors within the past 5 years or at the same time, except cured skin basal cell carcinoma, cervical carcinoma in situ and thyroid papillary carcinoma;\n6. Patient with serious heart disease;\n7. Other conditions deemed unsuitable for inclusion by the researcher.",{"count":221,"type":23},255,"This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can indicate recurrence earlier than imaging examination, and explore the feasibility of guiding adjuvant therapy after curative treatment based on this model.",[224],"Hepatocellular Carcinoma Resectable","2026-03-18",{"date":227,"type":39},"2026-03-20",{"date":229,"type":39},"2023-11-20",{"date":231,"type":23},"2028-11-30",{"name":45,"class":46},7,{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":114,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":240,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":106},"100627941","observational-clinical-study-on-the-association-between-lactate-mediated-gut-microbiota-alterations-and-disease-progression-in-liver-cirrhosis-100627941","NCT07455175","Observational Clinical Study on the Association Between Lactate-mediated Gut Microbiota Alterations and Disease Progression in Liver Cirrhosis.","Inclusion Criteria:\n\n\\- 1. Healthy individuals without a history of liver disease or related underlying disorders; or patients diagnosed with liver cirrhosis and its complications based on imaging and\u002For liver biopsy, with a history of chronic liver disease for more than 6 months. Etiologies include chronic hepatitis B virus infection, nonalcoholic fatty liver disease, and alcoholic liver disease, among others.\n\n2\\. Willing to participate in this study and able to provide written informed consent.\n\nExclusion Criteria:\n\n* 1\\. A history of severe organic diseases involving the liver, gastrointestinal tract, kidneys, or other organ systems; malignant tumors; or autoimmune diseases.\n\n  2\\. Patients with acute infection or inflammatory diseases within the past 1 month.\n\n  3\\. Pregnant or breastfeeding women.",{"count":241,"type":23},200,"To investigate the association between lactate-mediated alterations in the gut microbiota and disease progression in patients with liver cirrhosis; and to examine the correlations of lactate levels among serum, fecal, and tissue samples in patients with liver cirrhosis.",[244],"Cirrhosis","2026-03-03",{"date":247,"type":39},"2026-03-06",{"date":249,"type":23},"2026-04-01",{"date":251,"type":23},"2028-10-01",{"name":45,"class":46},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":114,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":265,"leadSponsor":267,"locationsCount":106},"100627939","an-observational-clinical-study-on-the-association-of-intestinal-ruminococcus-gnavus-and-its-derived-biogenic-amines-with-metabolic-dysfunction-associated-fatty-liver-disease-100627939","NCT07455149","An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines With Metabolic Dysfunction-associated Fatty Liver Disease","Inclusion Criteria:\n\n* 1.Healthy individuals without a history of liver disease or related underlying diseases; or patients diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) according to the latest guideline, Guidelines for the Prevention and Treatment of Metabolic (Dysfunction-Associated\u002FNon-Alcoholic) Fatty Liver Disease (2024 Edition), meeting the following criteria: (i) imaging-based diagnosis of fatty liver and\u002For liver biopsy showing ≥5% macrovesicular steatosis in hepatocytes; (ii) presence of at least one component of metabolic syndrome (MetS); and (iii) exclusion of other causes of fatty liver, including excessive alcohol consumption (weekly ethanol intake ≥210 g for men and ≥140 g for women), malnutrition, hepatolenticular degeneration (Wilson's disease), and other potential etiologies.\n\n  2.Willingness to participate in this study and to sign the informed consent form.\n\n  3.Age \\>18 years.\n\nExclusion Criteria:\n\n* 1\\. History of severe organic diseases in the liver, gastrointestinal tract, kidneys, or other systems, malignant tumors, or autoimmune diseases.\n\n  2\\. Patients who have had an acute infection or inflammatory disease within the past month.\n\n  3\\. Use of laxatives, antibiotics, probiotics, prebiotics, proton pump inhibitors, or other medications that may affect the gut microbiota within the past month.",{"count":241,"type":23},"Investigating the association between intestinal Ruminococcus gnavus and its derived biogenic amines with metabolic dysfunction-associated fatty liver disease",[262],"Metabolic Dysfunction-associated Fatty Liver Disease",{"date":247,"type":39},{"date":249,"type":23},{"date":266,"type":23},"2030-10-01",{"name":45,"class":46},{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":275,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":106},"100628089","impact-of-postoperative-radiotherapy-versus-pd-1-inhibitor-maintenance-on-survival-in-resectable-locally-advanced-oral-and-oropharyngeal-squamous-cell-carcinoma-100628089","NCT07457099","Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma","Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Patients With Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma Treated With Neoadjuvant Immunochemotherapy and Radical Surgery: A Single-Center Ambispective Cohort Study","Inclusion Criteria:\n\n1. Age 18-80 years, any gender.\n2. Expected survival ≥ 6 months.\n3. Adequate major organ function; ECOG performance status 0-1.\n4. Treatment-naïve patients diagnosed with locally advanced oral squamous cell carcinoma (LA-OSCC) or locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC), in accordance with the 8th edition of the American Joint Committee on Cancer (AJCC) staging system (2017) and the 2020 Chinese Stomatological Association (CSA) guidelines for pathological diagnosis of oral and oropharyngeal cancers, with clinical stages: cT3N0M0, cT1-3N1M0, cT4aN0-2M0, cT1-4aN3M0, or cT4bN0-3M0.\n5. No evidence of distant metastasis based on auxiliary examinations.\n6. No prior antitumor treatment, including surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, or other antitumor therapies.\n7. Received 2 cycles of neoadjuvant chemoimmunotherapy (toripalimab + TP regimen) and underwent R0 resection.\n8. Women of childbearing potential must agree to use effective contraception during treatment and for 3 months after.\n9. Signed informed consent (if the participant lacks capacity, by a legally authorized representative), voluntarily participates in the study, and demonstrates good compliance.\n\nExclusion Criteria:\n\n1. History of radiotherapy to the head and neck region.\n2. Severe bone marrow suppression, hepatic or renal failure, or uncontrolled severe infections, cardiovascular diseases, or other conditions that may preclude tolerance of treatment.\n3. Active autoimmune diseases, history of organ transplantation requiring long-term immunosuppressive therapy, or severe immunodeficiency that may result in serious immune-related adverse events.\n4. Active infections requiring systemic therapy.\n5. Cardiovascular\u002Fcerebrovascular events within 6 months prior to study treatment, including myocardial infarction, severe\u002Funstable angina, coronary or peripheral artery bypass surgery, symptomatic heart failure, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism.\n6. Bleeding tendency\u002Fdisorders: clinically significant bleeding or clear bleeding tendency within the past 28 days, including but not limited to gastrointestinal bleeding, epistaxis (excluding mild nosebleeds or blood-streaked sputum), or persistent bleeding\u002Fclotting disorders.\n7. History of substance abuse, alcoholism, or drug abuse.\n8. Pregnant or breastfeeding women.\n9. Participation in other interventional clinical trials simultaneously.",{"count":276,"type":23},85,"Neoadjuvant immunochemotherapy (NAIC) has demonstrated promising pathological and survival outcomes in patients with resectable locally advanced oral and oropharyngeal squamous cell carcinoma (LA-OSCC\u002FOPSCC). However, the optimal postoperative management strategy following NAIC and radical surgery remains undefined, particularly regarding the necessity of postoperative radiotherapy and the potential role of PD-1 inhibitor maintenance therapy.\n\nThis single-center, ambispective cohort study aims to compare event-free survival, pathological response, survival outcomes, failure patterns, treatment-related toxicities, and functional outcomes among three postoperative strategies: postoperative radiotherapy, postoperative PD-1 inhibitor maintenance, and observation alone. The study seeks to provide real-world evidence to support risk-adapted, individualized postoperative decision-making after NAIC",[279,280],"Locally Advanced Oral Squamous Cell Carcinoma","Locally Advanced Oropharyngeal Squamous Cell Carcinoma",[282,283,284,285,286,287,288,289],"Neoadjuvant immunochemotherapy","oral cancer","oropharyngeal cancer","PD-1 inhibitor","postoperative radiotherapy","event-free survival","pathological response","real-world study",{"date":291,"type":39},"2026-03-09",{"date":249,"type":23},{"date":294,"type":23},"2028-06-30",{"name":45,"class":46},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":18,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":307,"conditions":308,"keywords":311,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":323},"100618341","the-clinical-application-of-artificial-intelligence-assisted-renal-biopsy-diagnosis-system-100618341","NCT07330362","The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System.","The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Image Diagnosis System.","Inclusion Criteria:\n\n1. Voluntary signing of informed consent form;\n2. Patients clinically diagnosed or suspected of having chronic kidney disease according to the 2023 KDIGO Clinical Practice Guideline for the Evaluation and Management of Kidney Disease;\n3. Undergoing renal biopsy and pathological specimen preparation.\n\nExclusion Criteria:\n\n1. Biopsy tissue from donor kidney or transplanted kidney;\n2. Poor quality of pathological specimen, unable to conduct pathological diagnosis.","15 Years","79 Years",{"count":306,"type":23},2900,"This research project aims to collect images from patients with chronic glomerulonephritis. For each subject, the images obtained from renal biopsy will undergo evaluation by both the diagnostic model and the 'gold standard' diagnosis by pathologists. The researchers will test the subjects using the diagnostic model and compare the results with the known 'gold standard' diagnosis, in order to evaluate the AUC, specificity, and sensitivity of the diagnostic model.",[309,310],"Chronic Glomerulonephritis","Chronic Kidney Disease",[312,313,314],"Artificial intelligence","TEM-AID","glomerulonephritis","2026-01-25",{"date":317,"type":39},"2026-01-27",{"date":319,"type":39},"2024-07-01",{"date":321,"type":23},"2026-12-31",{"name":45,"class":46},2,{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":144,"enrollmentInfo":332,"targetDuration":4,"studyType":24,"phases":333,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":348,"locationsCount":106},"100620782","phase-1-luspatercept-for-the-treatment-of-anemia-following-allogeneic-hematopoietic-stem-cell-transplantationallo-hsct-100620782","NCT07362095","Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)","An Exploratory Study on the Safety and Efficacy of Luspatercept in the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia","Allo-HSCT","Inclusion Criteria:\n\n1. Clinically diagnosed with acute leukemia.\n2. Has undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT).\n3. Expected to survive for more than 3 months from the date of signing the informed consent form.\n4. Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, and has provided written informed consent.\n5. Women of childbearing potential must have a negative serum pregnancy test within prior to enrollment. Female subjects who are surgically sterile or postmenopausal for at least 2 years are considered not of childbearing potential. Male and female subjects of reproductive potential must agree to use effective contraception throughout the study period.\n6. Hemoglobin (Hb) level \\\u003C 80 g\u002FL.\n\nExclusion Criteria:\n\n1\\. Inadequate organ function, defined as:\n\n1. Creatinine clearance \\\u003C 60 mL\u002Fmin;\n2. Left ventricular ejection fraction (LVEF) \\\u003C 55%;\n3. Oxygen saturation (SpO₂) \\\u003C 92% on room air;\n4. Total bilirubin \\> 2 × the upper limit of normal (ULN);\n5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 × ULN. 2. Poorly controlled hypertension, defined as repeated systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg despite adequate antihypertensive therapy, or a history of hypertensive crisis or hypertensive encephalopathy.\n\n3\\. History of other malignancies (except for acute leukemia), unless the subject has been disease-free for ≥5 years. However, subjects with the following history\u002Fconcomitant conditions are eligible:\n\n1. Basal or squamous cell carcinoma of the skin;\n2. Carcinoma in situ of the cervix;\n3. Carcinoma in situ of the breast;\n4. Incidental histological finding of prostate cancer (T1a or T1b as defined by the TNM staging system);\n5. Solid tumors considered by the investigator to have no other known active disease.\n\n4\\. Major surgery within 8 weeks prior to enrollment. The subject must have fully recovered from any prior surgery.\n\n5\\. History of cerebrovascular accident (including ischemic, embolic, and hemorrhagic), transient ischemic attack, deep vein thrombosis (including proximal and distal), pulmonary or arterial embolism, arterial thrombosis, or other venous thrombosis within 6 months prior to enrollment. Note: Prior superficial thrombophlebitis is not an exclusion criterion.\n\n6\\. Uncontrolled epilepsy, history of cerebral ischemia\u002Fhemorrhage, cerebellar disease, or other active central nervous system disorders.\n\n7\\. Cardiac disease within 6 months prior to enrollment, including: myocardial infarction, uncontrolled angina, acute decompensated heart failure, New York Heart Association (NYHA) Class III-IV heart failure, or uncontrolled arrhythmia (as determined by the investigator).\n\n8\\. Uncontrolled active systemic fungal, bacterial, or viral infection. 9. Evidence of human immunodeficiency virus (HIV) infection, active hepatitis B, and\u002For active hepatitis C.\n\n10\\. History of pure red cell aplasia (PRCA) and\u002For anti-erythropoietin antibody.\n\n11\\. Any condition or concomitant medication that may interfere with the interpretation of study data.\n\n12\\. Known hypersensitivity to luspatercept or any of its excipients.",{"count":116,"type":23},[334,118],"PHASE1","This is a single-center, single-arm, prospective exploratory study designed to evaluate the safety and efficacy of luspatercept for the treatment of anemia following allogeneic hematopoietic stem cell transplantation in patients with acute leukemia. A total of 46 eligible subjects are planned to be enrolled. The primary efficacy endpoint is the proportion of patients achieving a hemoglobin increase of ≥1.5 g\u002FdL at 8 weeks post-transplantation (without transfusion support) compared to baseline (the average of 3 days prior to the first dose). Secondary endpoints include assessing the impact of luspatercept on time to hematopoietic engraftment (neutrophil and platelet) and recording safety indicators such as adverse events, graft-versus-host disease, and infections. Subjects will receive subcutaneous luspatercept at 1 mg\u002Fkg on day +7 and day +28 post-transplantation.",[337],"Acute Leukemia",[339,330,340,341],"Acute leukemia","Anemia","Luspatercept","2026-01-21",{"date":344,"type":39},"2026-01-23",{"date":346,"type":39},"2025-10-01",{"date":166,"type":23},{"name":45,"class":46},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":355,"targetDuration":4,"studyType":24,"phases":357,"briefSummary":359,"conditions":360,"keywords":362,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":4},"100618705","early-phase-1-a-clinical-study-of-humanized-cd19-car-t-cells-with-tlr2-for-the-treatment-of-adult-patients-with-naive-b-cell-acute-lymphoblastic-leukemialymphoma-who-are-intolerant-to-intensive-chemotherapy-100618705","NCT07335094","A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia\u002FLymphoma Who Are Intolerant to Intensive Chemotherapy","Inclusion Criteria:\n\n1. Newly treated patients with acute B-lymphocytic leukaemia\u002Flymphoma who are clinically determined to be unable to tolerate strong chemotherapy;\n2. age 18-80 years old (including boundary value), both men and women can;\n3. The physical status of the American Eastern Cancer Collaboration Group (ECOG) was 0\\~2 points;\n4. Positive CD19 confirmed by flow cytometry and\u002For histopathology;\n5. The expected survival period from the date of signing the informed consent form is more than 3 months.；\n6. women of childbearing age screening period human chorionic gonadotropin (HCG) test negative, and Consent to use contraception for at least 1 year after the infusion; A man whose partner is fertile Subjects must agree to use an effective barrier contraceptive method for at least 1 year after the infusion；\n7. the patient's main tissues and organs function well: (1) Liver function: ALT\u002FAST\\\u003C3 times the upper limit of normal (ULN) and total bilirubin ≤34.2μmol\u002FL; (2) Renal function: creatinine clearance (Cockcroft-Gault method) ≥60mL\u002Fmin; (3) Lung function: blood oxygen saturation ≥95%, and no active lung infection; (4) Cardiac function: left ventricular ejection fraction (LVEF) ≥50%; No large number of pericardium was found Fluid accumulation, no clinically significant electrocardiogram abnormalities；\n\nExclusion Criteria:\n\n1. severe cardiac insufficiency, left ventricular ejection fraction \\\u003C50%;\n2. have a history of severe lung function impairment;\n3. Combined with other advanced malignant tumors;\n4. Had severe infection within 4 weeks before enrollment and could not be effectively controlled;\n5. suffering from serious autoimmune diseases or immune deficiency diseases;\n6. active hepatitis (HBV DNA quantitative \\> 500IU\u002Fml\\] or HCV ribose Nucleic acid \\[HCVRNA\\] test positive);\n7. human immunodeficiency virus (HIV) infection or known to have acquired immunodeficiency syndrome Co-syndrom (AIDS), or syphilis infection;\n8. Have a history of severe allergy to biological products (including antibiotics), antibodies or cytokines Allergy to macromolecular biological drugs;\n9. Acute graft-versus-host reactions were still present one month after immunosuppressant discontinuation Patients with allogeneic hematopoietic stem cell transplantation (GvHD);\n10. in the pregnancy period (urine\u002Fblood pregnancy test positive) or breastfeeding women; nearly Men or women who plan to conceive within 1 year; Not guaranteed to be taken within 1 year after enrollment Effective contraception (condoms or contraceptives, etc.);\n11. History of clinically significant central nervous system diseases, such as epilepsy, paresis, and loss Speech, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic Cerebral syndrome;\n12. Suffering from mental illness;\n13. The patient has substance abuse\u002Faddiction;\n14. Use of banned drugs. (1). Hormones: within 7 days before leukocyte collection, or within 72 hours before CD19CAR-T administration A past therapeutic dose of corticosteroid (defined as prednisone or equivalent \\> 20mg\u002Fday) Days). However, the use of physiological substitutes, topical and inhaled steroids is permitted. (2) Chemotherapy: rescue chemotherapy was received within 2 weeks before white blood cell collection. (3) Allogeneic cell therapy: donor lymphocytes were received within 4 weeks before white blood cell collection Infusion. (4).GVHD treatment: Anti-GVHD received within 4 weeks prior to CD19CAR T cell infusion Heal. (5) Alenzumab was used within 6 months before white blood cell collection, or chlorine was used within 3 months Farabine or cladobine.",{"count":356,"type":23},60,[358],"EARLY_PHASE1","The purpose of this clinical trial is to tolerability and safety of humanized CD19 CAR-T therapy with TLR2 in adult patients with acute B lymphoblastic leukemia\u002Flymphoma who cannot tolerate intense chemotherapy at initial treatment. Participants will receive a single infusion of CD19 CAR-T and complete follow-ups over the next three years.",[361],"B Lymphoblastic Leukemia\u002FLymphoma",[363,364],"CAR-T","CD19","2026-01-04",{"date":367,"type":39},"2026-01-12",{"date":369,"type":23},"2026-06-01",{"date":371,"type":23},"2029-06-01",{"name":45,"class":46},{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":144,"enrollmentInfo":381,"targetDuration":4,"studyType":24,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":393,"locationsCount":4},"100612747","tdcs-rtms-intervention-for-motor-function-100612747","NCT07257601","TDCS-RTMS Intervention for Motor Function","The Effect of Transcranial Direct Current Stimulation Combined With Repetitive Transcranial Magnetic Stimulation on Motor Function Rehabilitation in Patients With Locked-in Syndrome","TRIMLiS","Inclusion Criteria:\n\n* The patients were 18-70 years old, clinically diagnosed as classic or incomplete atresia syndrome, and the onset time was 6 weeks-1 year.\n* Clear consciousness, effective communication and command response through eye movement or other established methods.\n* No drugs (sodium, calcium channel blockers or sedatives) that may affect neuromuscular function or brain stimulation effect were used, or the drugs were stably stopped for more than 1 week before enrollment.\n* The patient or his legal guardian signed the informed consent form and agreed to cooperate in completing all test procedures and evaluations.\n\nExclusion Criteria:\n\n* Metal implants (such as cardiac pacemaker, intracranial metal clip, etc.), electronic equipment or other TMS contraindications.\n* Complicated with severe cognitive impairment (such as dementia) or unable to cooperate to complete the assessment scale test.\n* Have a history of severe cardiopulmonary dysfunction, mental illness and seizures.\n* There are other neurodegenerative diseases that affect the recovery of motor function (such as amyotrophic lateral sclerosis, etc.)\n* Recently (within 1 month) participated in other clinical trials related to neuromodulation therapy.",{"count":382,"type":23},72,[89],"This study was a multicenter randomized double-blind, sham controlled trial initiated by Zhujiang Hospital of Southern Medical University. It is planned to recruit 72 eligible patients with atresia syndrome and randomly divide them into four groups according to the ratio of 1:1:1:1. Group 1 received the sequential stimulation of true tDCS and true rTMS, group 2 received the stimulation of sham tDCS and then true rTMS, group 3 received the stimulation of true tDCS and then sham rTMS, and group 4 received the simulated stimulation of sham tDCS and sham rTMS. The patients were treated for 4 weeks, 5 days a week, once a day in the bilateral M1 area, and in the morning and afternoon on the left and right sides respectively. Each tDCS and rTMS treatment lasted for 20 minutes.Various indicators were evaluated before and after the intervention, and the observation and follow-up were conducted 1, 3, and 6 months after the intervention.",[386],"Locked in Syndrome","2025-12-02",{"date":389,"type":39},"2025-12-10",{"date":391,"type":23},"2025-11-30",{"date":190,"type":23},{"name":45,"class":46},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":144,"enrollmentInfo":401,"targetDuration":4,"studyType":24,"phases":403,"briefSummary":404,"conditions":405,"keywords":407,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":106},"100610821","phase-1-exploratory-study-of-intranasal-administration-of-human-umbilical-cord-mesenchymal-stem-cell-derived-extracellular-vesicles-for-the-treatment-of-ischemic-stroke-100610821","NCT07232563","Exploratory Study of Intranasal Administration of Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Treatment of Ischemic Stroke","Exploratory Study of Intranasal Administration of Small Extracellular Vesicles Derived From Human Umbilical Cord Mesenchymal Stem Cells hUC-MSC-sEV-001 in the Treatment of Ischemic Stroke Patients","Inclusion criteria:\n\n* Ischemic Stroke\n* Age 18-70 years, no gender restriction\n* Confirmed anterior circulation occlusion by CTA or MR angiography (MRA)\n* Pre-stroke mRS score of 0-1\n* Post-stroke ASPECTS score \\>= 6\n* Pre-enrollment NIHSS score\\>= 6\n* Within 24 hours to 14 days of stroke onset\n* Patients who have not received thrombolysis or endovascular treatment\n* No significant liver or kidney dysfunction: ALT and AST\\\u003C= 2.5 times the upper limit of normal, serum creatinine and blood urea nitrogen \\\u003C= 1.25 times the upper limit of normal\n* No significant cardiac dysfunction\n* The subject or legal representative can sign the informed consent form and comply with the requirements of the study for administration and follow-up.\n\nExclusion criteria:\n\n* Intracranial hemorrhagic conditions observed on cranial CT: hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, or hemorrhagic transformation, etc.\n* Known severe allergy to contrast agents (excluding mild rash-type allergies)\n* Known bleeding tendencies (including but not limited to): platelet count \\\u003C 100×10\\^9\u002FL; received heparin treatment within 48 hours with aPTT \\>= 35s; currently taking warfarin with INR \\> 1.7\n* Patients with brain tumors, or a history of epilepsy and severe head trauma\n* Patients with other systemic malignancies\n* Patients with other serious systemic diseases such as immunodeficiency, coagulation disorders, etc.\n* Patients with Alzheimer's disease, Parkinson's disease, or other neurodegenerative diseases that prevent them from completing follow-up\n* Patients with severe local infection, systemic infection, immunodeficiency, or those currently taking immunosuppressants\n* Patients who are positive for hepatitis B surface antigen or currently suffering from other infectious diseases\n* Patients who have allergic reactions to the drug used in this study or similar drugs\n* Patients with known allergic constitution\n* Patients with nasal structural abnormalities or lesions\n* Patients with cerebrospinal fluid rhinorrhea\n* Patients who have participated in other clinical trials within the past 3 months\n* Unwilling or unable to comply with the procedures specified in the protocol\n* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling or unable to use appropriate contraceptive measures\n* Patients clearly lacking the compliance to complete the clinical trial, such as those suffering from uncontrolled mental illness\n* Other situations deemed unsuitable for enrollment by the researchers",{"count":402,"type":23},9,[334],"Evaluation of the Safety and Preliminary Efficacy of Intranasal Administration of Human Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles (hUC-MSC-sEV-001) in Patients for Ischemic Stroke",[406],"Ischemic Stroke",[408,409,410],"ischemic stroke","stem cell","Extracellular Vesicles","2025-11-14",{"date":413,"type":39},"2025-11-18",{"date":415,"type":23},"2025-12-01",{"date":417,"type":23},"2027-11-07",{"name":45,"class":46},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":425,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":427,"conditions":428,"keywords":429,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":106},"100601512","prospective-cohort-study-on-oral-microbiome-changes-in-patients-with-locally-advanced-oral-squamous-cell-carcinoma-following-neoadjuvant-chemoimmunotherapy-100601512","NCT07111455","Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy","Inclusion Criteria:\n\n1. Oral squamous cell carcinoma (OSCC) diagnosed as locally advanced (T3N0M0, T1-3N1M0, T4aN0-2M0, T1-4aN3M0, or T4bN0-3M0) according to AJCC staging criteria.\n2. Their age ranged from 18 to 80 years;regardless of gender.\n3. Absence of prior head and neck radiation therapy or chemotherapy.\n4. Adequate blood function: white blood cell count (WBC) \\>＝3.5×10\\^9\u002FL, platelet count (PLT) \\>＝75×10\\^9\u002FL：Hemoglobin concentration (HGB) \\>＝90g\u002FL.\n5. Adequate liver function： total bilirubin (TBIL) \\\u003C＝ the upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C＝2.5 times the upper limit of normal.\n6. Adequate renal function：estimated glomerular filtration rate (eGFR) greater than 45 mL\u002Fmin per 1.73 m².\n7. The heart, brain, lung and other vital organs function and general condition can tolerate NACI.\n8. PS score \\\u003C＝2.\n9. Signed informed consent form and voluntarily agreeing to participate in this study.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation (for female participants).\n2. Patients with a history of epilepsy or psychiatric disorders that were not well-controlled.\n3. Patients with severe allergic diathesis or suspected or confirmed alcohol or drug addiction.\n4. Patients who had taken antibiotics within 7 days before enrollment.",{"count":426,"type":23},32,"Investigating the Relationship Between Oral Microbiome Alterations and Tumor Markers in Locally Advanced Oral Squamous Cell Carcinoma (LA-OSCC) After Neoadjuvant Chemoimmunotherapy: Implications for Therapeutic Efficacy, Chemoresistance, and Prognostic Assessment",[279],[430,431],"Oral Microbiome","Neoadjuvant Chemoimmunotherapy","2025-09-21",{"date":434,"type":39},"2025-09-23",{"date":436,"type":39},"2025-07-22",{"date":438,"type":23},"2027-07-30",{"name":45,"class":46},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":446,"targetDuration":4,"studyType":24,"phases":448,"briefSummary":450,"conditions":451,"keywords":453,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":461,"locationsCount":106},"100565650","phase-2-single-arm-clinical-trial-of-tace-in-combination-with-icaritin-as-adjuvant-therapy-after-surgery-in-patients-with-hepatocellular-carcinoma-at-high-risk-of-recurrence-100565650","NCT06644937","Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence","Inclusion Criteria:\n\n1. The subjects voluntarily cooperated with the study and signed the informed consent,\n2. Male or female, 18 years old ≤ age ≤75 years old,\n3. The histopathologic diagnosis was hepatocellular carcinoma\n4. R0 resection was performed within 4 to 8 weeks before recruitment (patients who were confirmed to have R0 resection by imaging and pathological examination were excluded from the study group if the residual R1, residual R2 or the margin of resection were not clear)\n5. To satisfy any of the following high risk factors for postoperative recurrence of hepatocellular carcinoma:\n\n   I) BCLC stage B (\\> 3 tumors, regardless of size or number, at least one of which is \\> 3 cm in diameter) ; ii) single tumor ≥5 cm in diameter; III) intraoperative or postoperative pathological findings of vascular invasion (including microvascular invasion and VP1\u002FVP2 portal vein invasion) ; IV) histopathologic grade of low differentiation; v) capsular invasion or loss with unclear border; VI) direct invasion of adjacent organs\n6. ECOG performance status score of 0-1 and Child-Pugh score of 5-6\n7. None of the patients had received anti-tumor therapy for hepatocellular carcinoma, including systemic therapy and local therapy (except for 1-2 prophylactic TACE or HAIC 4-8 weeks after radical therapy) .\n8. Subjects who received radical therapy, if required, were allowed to receive 1-2 prophylactic TACE\u002FHaic treatments 4-8 weeks after surgery (on demand and not necessarily)\n\nExclusion Criteria:\n\n1. Known sarcomatoid hepatocellular carcinoma\u002Fmixed hepatocellular carcinoma-cholangiocarcinoma\u002Ffibrolamellar hepatocellular carcinoma;\n2. A history of other malignancies in the past 5 years or at the same time;\n3. Severe functional impairment of other important organs such as heart, brain, lung and kidney;\n4. Patients with a history of immunodeficiency or autoimmune disease;\n5. Evidence of tumor recurrence or metastasis before enrollment;\n6. Known hypersensitivity to active ingredients, excipients, or history of severe allergy to any other monoclonal antibody, anti-angiogenic drugs;\n7. Patients with a history of hepatic encephalopathy;",{"count":447,"type":23},30,[118,449],"PHASE3","To assess 1-year recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) who are at high risk of Inguinal orchiectomy recurrence usingTACE combined with icaritin",[452],"Hepatocellular Carcinoma (HCC)",[454,455,456],"hepatocellular carcinoma","RFS","adjuvant therapy after surgery",{"date":434,"type":39},{"date":459,"type":39},"2024-11-29",{"date":321,"type":23},{"name":45,"class":46},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":55,"enrollmentInfo":469,"targetDuration":4,"studyType":24,"phases":470,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":106},"100460021","phase-1-single-arm-study-of-post-transplant-azacitidine-and-chidamide-for-prevention-of-acute-myelogenous-leukemia-relapse-100460021","NCT05270200","Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse","To Evaluate Safety and Efficiency of AZA Combined With Chidamide as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation：A Multicenter, Single-arm Study","Inclusion Criteria:\n\n* 1.Age 18 to 60 years old,both male and female\n* 2.Be able to understand and sign informed consent\n* 3.Patients with a diagnosis of AML not M3 according to the 2016 World Health Organization (WHO) Acute Myeloid Leukemia Classification and Diagnostic\n* 4.Patients have AML with poor genetic abnormalities,primary refractory AML,relapsed AML or secondary AML\n* 5.Patients with an ECOG performance status 0,1,2 or 3\n* 6.Expected survival time ≥ 3 months\n* 7.Non-hematological toxicity related to transplantation does not exceed Grade 2\n* 8.Laboratory indicators meet the following standards:\n\n  1. 7 days before the first day of the first course of treatment, bilirubin, ALT and AST were all less than 3 times the upper limit of normal.\n  2. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, the neutrophil count are greater than 1.5×10\u002FL and without G-CSF treatment.\n  3. Measure twice within 7 days before the first day of the first course of treatment, at least 2 days apart, platelet count greater than 80×10\u002FL and without platelet transfusion.\n  4. Serum creatinine clearance rate is greater than 30ml\u002Fmin.\n\nExclusion Criteria:\n\n* 1.Uncontrollable active infection\n* 2.Patients with active hepatitis B or C or HIV infection before enrollment\n* 3.Have a grade III-IV graft-versus-host disease",{"count":201,"type":23},[334,118],"The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.",[473],"Leukemia, Myeloid, Acute",[475,476,477,478,479,480],"Acute myelogenous leukemia","Allogenetic stem cell transplant","Maintenance therapy","Azacitidine","Chidamide","High-risk AML",{"date":482,"type":39},"2025-09-25",{"date":484,"type":39},"2022-02-01",{"date":43,"type":23},{"name":45,"class":46},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":24,"phases":495,"briefSummary":496,"conditions":497,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":4},"100602827","phase-2-romiplostim-n01-for-the-treatment-of-thrombocytopenia-associated-with-radiotherapy-combined-treatment-regimens-in-patients-with-solid-tumors-100602827","NCT07128576","Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors","A Multicenter Phase II Clinical Study of Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors","Inclusion Criteria:\n\n* Age ≥18 years, regardless of gender; Histopathologically confirmed solid tumor patients (including but not limited to nasopharyngeal carcinoma, lung cancer, breast cancer, etc.);\n* Prior radiotherapy (RT) ≥45Gy (including standalone RT, concurrent\u002Fsequential chemoradiotherapy, or RT combined with other antitumor therapies, with treatment duration ≥2 weeks), regardless of prior induction\u002Fadjuvant chemotherapy;\n* Platelet count \\\u003C75×10⁹\u002FL within 3 days prior to enrollment, occurring during RT or within 1 month post-RT;\n* Estimated survival ≥12 weeks at screening;\n* ECOG score 0, 1, or 2;\n* Premenopausal women\u002Fmen of childbearing potential must agree to contraceptive measures during and for 6 months post-study; non-lactating patients;\n* No participation in other drug clinical trials within 4 weeks prior to enrollment;\n* Voluntary signing of informed consent after full comprehension of study requirements.\n\nExclusion Criteria:\n\n* Patients with hematologic diseases, including lymphoma, leukemia, aplastic anemia, primary immune thrombocytopenia (ITP), myeloproliferative disorders, multiple myeloma, or myelodysplastic syndromes;\n* Patients who experienced thrombocytopenia within 6 months prior to screening due to non-cancer treatments, including but not limited to EDTA-dependent pseudo-thrombocytopenia, hypersplenism, infection, or bleeding.\n* Patients with brain tumors, brain metastases, bone marrow invasion, or bone marrow metastases;\n* Patients with hemoglobin \\\u003C50 g\u002FL after red blood cell transfusion or erythropoietin (EPO) treatment, or absolute neutrophil count \\\u003C1.0×10⁹\u002FL after granulocyte colony-stimulating factor (G-CSF) treatment;\n* Patients who experienced any arterial or venous thrombosis within 6 months prior to screening;\n* Patients with severe cardiovascular diseases within 6 months prior to screening (e.g., NYHA Class III-IV heart failure), high-risk arrhythmias (e.g., atrial fibrillation), coronary stent placement, angioplasty, or coronary artery bypass grafting;\n* Patients who received platelet transfusion within 5 days prior to enrollment;\n* Patients who received thrombopoietin receptor agonist treatment within 4 weeks prior to study drug administration, recombinant human thrombopoietin (rhTPO) or rhIL-11 within 4 weeks prior to enrollment, or other platelet-enhancing traditional Chinese medicine within 1 week prior to enrollment;\n* Patients with positive hepatitis C antibody and detectable HCV-RNA, positive hepatitis B surface antigen and detectable HBV-DNA, severe cirrhosis, HIV antibody positivity, or syphilis antibody positivity;\n* Patients with ALT and AST ≥3×ULN (for subjects without liver metastasis) or ≥5×ULN (for subjects with liver metastasis) during screening;\n* Patients with serum creatinine ≥1.5×ULN or estimated glomerular filtration rate (eGFR) ≤60 mL\u002Fmin;\n* Patients with known allergies or intolerances to the active ingredients or excipients of romiplostim N01 for injection;\n* Patients who are pregnant, planning pregnancy, or breastfeeding;\n* Patients deemed unsuitable for participation in the trial by the investigator.",{"count":356,"type":23},[118],"With the development of modern medicine, targeted and immunotherapies have been widely adopted in clinical practice. Beyond conventional chemotherapy combination regimens, the integration of radiotherapy into multimodal treatment strategies has also expanded significantly.\n\nWhile robust evidence supports the use of romiplostim for managing chemotherapy-induced thrombocytopenia (CIT), there is currently no clinical research evaluating its efficacy in treating thrombocytopenia associated with radiotherapy-combined treatment regimens in solid tumors.\n\nTo address this unmet clinical need, this study aims to evaluate the safety and efficacy of romiplostim N01 for injection in the treatment of radiotherapy-combined regimen-induced thrombocytopenia in solid tumor patients. The findings will establish evidence-based management strategies to optimize clinical decision-making in this context.",[498],"Solid Tumors","2025-08-28",{"date":501,"type":39},"2025-09-04",{"date":503,"type":23},"2025-09-15",{"date":505,"type":23},"2028-12-31",{"name":45,"class":46},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":514,"targetDuration":516,"studyType":58,"phases":4,"briefSummary":517,"conditions":518,"keywords":521,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":531,"locationsCount":106},"100603241","a-bidirectional-observational-clinical-study-of-naic-in-the-treatment-of-tumor-regression-patterns-in-la-oscc-and-la-opscc-100603241","NCT07133958","A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC","A Bidirectional Observational Clinical Study of Tumor Regression Patterns in Patients With Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma Treated With Neoadjuvant Immunochemotherapy","Inclusion Criteria:\n\n1. Oral squamous cell carcinoma or oropharyngeal squamous cell carcinoma diagnosed as locally advanced (T3-4) according to the AJCC criteria\n2. Their age ranged from 18 to 80 years\n3. There was no history of other malignant tumors or treatment\n4. Adequate blood function: white blood cell count (WBC) ≥3.5×10\\^9\u002FL, platelet count (PLT) ≥75×10\\^9\u002FL; Hemoglobin concentration (HGB) ≥90g\u002FL\n5. Adequate liver function: total bilirubin (TBIL) ≤ the upper limit of normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper limit of normal\n6. \"Adequate renal function: urinary white blood cells \\\u003C 10, red blood cells \\\u003C 10, cast count \\\u003C 5 per high-power field, and creatinine (CRE) ≤ the upper limit of normal.\n7. The heart, brain, lung and other vital organs function and general condition can tolerate NACI and surgical treatment\n8. PS score ≤2\n\nExclusion Criteria:\n\n1. Presence of distant metastasis\n2. Women who are pregnant or lactating\n3. Patients who are unable to cooperate with regular follow-up due to psychological, social, family and geographical reasons\n4. Receiving investigational treatment in addition to other clinical studies (in the treatment phase of a clinical study)\n5. Accompanied by severe uncontrolled infection or medical illness\n6. Major organ dysfunction, such as decompensated heart, lung, kidney, and liver failure, cannot tolerate NACI or surgical treatment\n7. There are factors affecting surgery or anesthesia, such as severe organ dysfunction\n8. Long-term use of immunosuppressive agents after organ transplantation\n9. Patients with a history of other malignant tumors before enrollment",{"count":515,"type":23},35,"2 Years","A prospective collection of 35 cases was conducted at Zhujiang Hospital of Southern Medical University. Patients diagnosed with locally advanced oral squamous cell carcinoma (LA-OSCC) or locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC) from April 2023 onward, who received two cycles of neoadjuvant immunochemotherapy (tislelizumab + paclitaxel + cisplatin\u002Fcarboplatin) at our institution, were included. The study analyzed treatment safety, efficacy, tumor regression patterns, 2-year progression-free survival (PFS), and 5-year overall survival (OS) rates.",[519,520],"Oral Squamous Cell Carcinoma (OSCC)","Oropharyngeal Squamous Cell Carcinoma (SCC)",[522,523,524],"Oral squamous cell carcinoma","Oropharyngeal squamous cell carcinoma","neoadjuvant immunochemotherapy","2025-08-14",{"date":527,"type":39},"2025-08-21",{"date":529,"type":39},"2023-07-11",{"date":43,"type":23},{"name":45,"class":46},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":538,"targetDuration":516,"studyType":58,"phases":4,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":323},"100557565","risk-assessment-and-mechanism-analysis-of-intracranial-multiple-aneurysm-instability-based-on-high-resolution-magnetic-resonance-imaging-histology-and-hemodynamics-100557565","NCT06539767","Risk Assessment and Mechanism Analysis of Intracranial Multiple Aneurysm Instability Based on High-resolution Magnetic Resonance, Imaging Histology and Hemodynamics","Inclusion Criteria:\n\n* Age 18-80 years old, male or infertile female;\n* Diagnosed as IA (intracranial aneurysm) through CTA, MRA, or DSA; And it is suitable for endovascular intervention treatment\n* The patient and\u002For their legal representative or guardian fully understand the research purpose, voluntarily participate and sign informed consent Books;\n* Patients willing to cooperate with high-resolution magnetic resonance imaging.\n* Patients willing to follow up and evaluate according to clinical research protocol requirements\n\nExclusion Criteria:\n\n* AVM (arteriovenous malformation), Moyamoya disease, or DAVF (dural arteriovenous fistula) related aneurysms;\n* Patients with contraindications for high-resolution magnetic resonance imaging;\n* Participants in clinical trials of other drugs or medical devices;\n* Patients with severe underlying diseases and extremely poor clinical conditions who cannot tolerate general anesthesia surgery;\n* Patients with poor compliance and inability to cooperate with follow-up;\n* Possible or clear history of severe allergy to contrast agents;\n* Patients with a life expectancy of less than 2 years;\n* Women who are breastfeeding and preparing for pregnancy during the study period",{"count":539,"type":23},1000,"This project proposes to establish a prospective cohort of MIA based on a preexisting multicenter MIA database and to combine multidimensional methods such as high-resolution magnetic resonance, hemodynamics, ambulatory blood pressure, and imaging histology to study aneurysm instability.",[542],"Arterial Aneurysm Wall Enhancement on HRMRI","2025-07-24",{"date":545,"type":39},"2025-07-28",{"date":547,"type":39},"2023-01-01",{"date":549,"type":23},"2025-12-31",{"name":45,"class":46},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":24,"phases":561,"briefSummary":562,"conditions":563,"keywords":570,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":4},"100550486","phase-3-interleukin-6-receptor-inhibition-for-symptomatic-intracranial-atherosclerosis-100550486","NCT06447701","Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis","Effect of Interleukin-6 Receptor Inhibition for Avoiding Recurrence of Ischemic Stroke in Patients With Symptomatic Intracranial Atherosclerosis: a Double-blind, Randomized, Placebo-controlled Trial","IRIS-sICAS","Inclusion Criteria:\n\n* Male or non-pregnant women with acute stroke symptoms aged over 18 years.\n* Patients having an ischemic stroke or a TIA prior to randomization (Patients having an acute ischemic stroke within 72 hours with NIHSS score≤5 at baseline, or patients having a TIA within 72 hours with Oxfordshire Community Stroke Project on the basis of age, blood pressure, clinical features, and duration of TIA symptoms (ABCD2) score≥4 at baseline).\n* The entry event is attributed to symptomatic atherosclerosis (50-99%) in an intracranial qualifying artery (intracranial carotid artery (C4-7), middle cerebral artery (M1), intracranial vertebral artery or basilar artery) confirmed by CT, MR angiography, or digital subtraction angiography.\n* Informed consent obtained from patients or their legal representatives.\n* Willing to be followed up as required by the clinical study protocol.\n\nExclusion Criteria:\n\n* Thrombolytic therapy or thrombectomy within 24 hours prior to enrollment.\n* Pre-stroke mRS score ≥ 2.\n* Combined or previous intracranial hemorrhage: hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.\n* Any of the following unequivocal cardiac source of embolism: chronic or paroxysmal atrial fibrillation, sinus node dysfunction, mitral stenosis, prosthetic heart valves, endocarditis, left ventricular mural thrombus or valvular vegetation, myocardial infarction within three months, dilated cardiomyopathy, spontaneous echogenic defects in the left atrium or an ejection fraction of less than 30%.\n* Intracranial arterial stenosis due to arterial dissection, Moya Moya disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; radiation induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; post-partum angiopathy; suspected vasospastic process, suspected recanalized embolus; any known vasculitic disease.\n* Extracranial stenosis ≥50%, subclavian arterial stenosis≥50% or subclavian steal syndrome.\n* Previous interventions for intracranial arterial stenosis.\n* Concurrent intracranial tumors, intracranial aneurysms or arteriovenous malformations\n* Neutrophil \\\u003C 2×10 9\u002FL.\n* Platelet \\\u003C 100×10 9\u002FL.\n* Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal.\n* Active infections including localized.\n* Evidence of HIV or hepatitis B positivity.\n* Positive tuberculosis-related tests.\n* Concurrent peptic ulcer, diverticulitis or inflammatory bowel disease.\n* Concurrent malignant tumors, recent bone marrow transplant or recent organ transplant.\n* Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg despite blood pressure control.\n* Known allergy to tocilizumab or excipients.\n* Use of immunosuppressive drugs or systemic use of antibiotics.\n* Received any live or live attenuated vaccine within 4 weeks prior to enrollment or plan to receive a live or live attenuated vaccine during the study.\n* History of demyelination or presence of neurological symptoms suggestive of demyelination.\n* Previously existing neurological or psychiatric disorders that could potentially confuse neurological function assessment.\n* An expected survival less than 90 days.\n* Participation in another interventional clinical study.\n* Patients unsuitable for enrollment in the clinical trial according to investigators decision making.",{"count":560,"type":23},486,[449],"IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.",[564,406,565,566,567,568,569],"Brain Diseases","Ischemia","Stroke","Cerebral Infarction","Atherosclerosis of Artery","Atheroscleroses, Intracranial",[571,572,573,574],"Tocilizumab","Symptomatic intracranial atherosclerotic stenosis","Recurrence","Ischemic stroke",{"date":545,"type":39},{"date":577,"type":23},"2025-10-30",{"date":579,"type":23},"2029-06-30",{"name":45,"class":46},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":589,"targetDuration":591,"studyType":58,"phases":4,"briefSummary":592,"conditions":593,"keywords":600,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":608,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":106},"100548261","the-correlation-of-intracranial-artery-calcification-and-outcomes-of-mechanical-thrombectomy-100548261","NCT06418698","The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy","The Prediction of Intracranial Artery Calcification on Adverse Outcomes of Large Vessel Occlusive, Acute Ischemic Stroke Patients After Mechanical Thrombectomy: A Prospective Cohort, Observational Study","CAIS-MT","Inclusion Criteria:\n\n* Male or non-pregnant women with acute stroke symptoms aged over 18 years.\n* Occlusion of the intracranial internal carotid artery, the middle cerebral artery, the anterior cerebral artery, the posterior cerebral artery, basilar artery and intracranial vertebral artery confirmed by CT, MR angiography, or digital subtraction angiography.\n* No absolute contraindication to iodinated contrast media.\n* Planned treatment with EVT by clinical care team.\n* Informed consent obtained from patients or their legal representatives.\n* Willing to be followed up as required by the clinical study protocol.\n\nExclusion Criteria:\n\n* Acute ischemic stroke occurs over 24 hours of time last known well.\n* Neurologic deficits caused by diagnoses other than ischemic stroke, such as intracerebral hemorrhage, subarachnoid hemorrhage, or intracranial tumors.\n* With other underlying factors leading to IAC, such as hyperthyroidism, end-stage renal disease, long-term oral intake of vitamin K antagonist(Warfarin), chronic vitamin D deficiency or overdose, persistent hypomagnesemia, persistent hypercalcemia, persistent hyperphosphatemia and high oral calcium intake.\n* Lack of non-contract CT images on admission and significant artifacts in CT images preventing IAC measurement.\n* Severe renal insufficiency (estimated glomerular filtration rate \\\u003C 30ml\u002Fmin or serum creatinine \\> 220μmol\u002FL (2.5mg\u002Fdl)).\n* Previous cerebrovascular intervention treatment or craniotomy.",{"count":590,"type":23},434,"3 Years","CAIS-MT is a single-center, prospective cohort study, to evaluate the correlation between outcomes of endovascular treatment(EVT) and intracranial artery calcification(IAC) in patients with acute ischemic stroke due to large or medium vessel occlusion.",[594,406,595,596,597,566,564,598,599],"Stroke, Acute","Vascular Diseases","Central Nervous System Diseases","Nervous System Diseases","Cerebrovascular Disorders","Intracranial Arterial Calcification",[601,602,603,604,605,606,607],"Acute ischemic stroke","Large vessel occlusion","Mechanical thrombectomy","Endovascular treatment","Agatston score","Prospective cohort study","Intracranial atherosclerotic disease",{"date":545,"type":39},{"date":610,"type":39},"2024-03-28",{"date":612,"type":23},"2029-06",{"name":45,"class":46},{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":4,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":18,"minAge":621,"maxAge":85,"enrollmentInfo":622,"targetDuration":4,"studyType":24,"phases":623,"briefSummary":624,"conditions":625,"keywords":627,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":323},"100598515","phase-1-cd19-car-t-cell-infusion-as-consolidation-therapy-in-adolescent-and-adult-patients-with-acute-b-all-ineligible-for-allogeneic-hsct-a-clinical-study-100598515","NCT07072494","CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study","Clinical Study on the Efficacy and Safety of CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-Lymphoblastic Leukemia Who Are Ineligible for Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. The subject has voluntarily agreed to participate, signed the informed consent form, and is willing and able to comply with scheduled visits, study treatment, laboratory tests, and other study procedures.\n2. The subject has been clinically diagnosed with newly diagnosed or refractory\u002Frelapsed B-cell acute lymphoblastic leukemia (B-ALL), including Burkitt lymphoma leukemia and blast-phase chronic myeloid leukemia, and has achieved complete remission (defined as \\\u003C5% bone marrow blasts, no peripheral blood blasts, and no extramedullary leukemia) after chemotherapy or immunotherapy, but is either ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT), lacks a suitable donor, or declines transplantation.\n3. Aged between 14 and 80 years (inclusive), male or female.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n5. At the time of screening, leukemia cells in the bone marrow or peripheral blood must be confirmed as CD19-positive by flow cytometry at initial or relapse diagnosis.\n6. An expected survival of more than three months from the date of signing the informed consent form.\n7. Satisfactory liver, kidney, cardiac, and pulmonary function, defined as:\n\n   1. Creatinine ≤2× upper limit of normal (ULN);\n   2. Left ventricular ejection fraction (LVEF) ≥50%;\n   3. Blood oxygen saturation \\>92%;\n   4. Total bilirubin ≤2× ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3× ULN.\n8. Adequate venous access for cell collection and meeting the following hematologic criteria:\n\n   Hemoglobin ≥80 g\u002FL Absolute neutrophil count (ANC) ≥1.0 × 10⁹\u002FL Platelet count ≥75 × 10⁹\u002FL If the above criteria are not met, the investigator may determine eligibility for mononuclear cell collection.\n9. Female subjects of childbearing potential must have a negative serum pregnancy test (women who have undergone surgical sterilization or have been postmenopausal for at least two years are considered non-fertile). Male and female subjects of reproductive potential must agree to use contraception during the study.\n\nExclusion Criteria:\n\n1. Presence of mixed-lineage leukemia or biphenotypic leukemia.\n2. Prior treatment with CAR-T cell therapy before screening or conditioning.\n3. Patients with bone marrow failure syndromes associated with genetic disorders, such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndromes.\n4. Any of the following viral infections:\n\n   Hepatitis B virus (HBV) DNA detectable above the lower limit of quantification. Positive hepatitis C virus antibody (HCV-Ab). Epstein-Barr virus (EBV) or cytomegalovirus (CMV) DNA detectable above the lower limit of quantification.\n\n   Positive human immunodeficiency virus (HIV) antibody test.\n5. History of or current malignancy within the past five years (excluding patients with a low risk of recurrence after curative treatment and more than five years of follow-up, as determined by the investigator).\n6. Any of the following cardiac conditions:\n\n   New York Heart Association (NYHA) Class III or IV congestive heart failure. Severe arrhythmia requiring treatment or clinically significant conduction abnormalities on ECG, including QTc interval ≥480 ms (QTcB = QT\u002F√RR).\n\n   Uncontrolled hypertension despite standard treatment (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg) or pulmonary hypertension.\n\n   Unstable angina. Myocardial infarction, coronary artery bypass grafting, or stent placement within six months before cell infusion.\n\n   Clinically significant valvular heart disease. Other cardiac diseases deemed inappropriate for study participation by the investigator.\n7. Uncontrolled epilepsy, a history of cerebrovascular ischemia\u002Fhemorrhage, cerebellar disease, or other active central nervous system (CNS) disorders.\n8. Clinically significant pericardial or pleural effusion at screening.\n9. History of deep vein thrombosis or pulmonary embolism within six months before screening.\n10. Known hypersensitivity to any component of the study treatment.\n11. Live vaccine administration within six weeks before screening.\n12. Severe, uncontrolled, active infection at screening.\n13. Participation in other interventional clinical trials and receipt of an investigational agent, including:\n\n    An unapproved investigational drug within three months before cell infusion. A marketed drug within fewer than five half-lives before cell infusion.\n14. Any other conditions deemed unsuitable for study participation by the investigator.\n15. Physical or cognitive conditions that impair the ability to provide informed consent or comply with study procedures, or unwillingness or inability to adhere to study requirements.","14 Years",{"count":447,"type":23},[334,118],"This clinical study investigates a novel treatment option for adolescents and adults with acute B-lymphoblastic leukemia (B-ALL). While allogeneic hematopoietic stem cell transplantation (HSCT) is a standard therapy for leukemia, some patients are ineligible due to factors such as age, underlying medical conditions, or the absence of a suitable donor. For these individuals, CD19 CAR-T cell therapy is being evaluated as a potential consolidation therapy.",[626],"Acute Lymphoblastic Leukemia",[628,364,626],"Chimeric Antigen Receptor T-Cell Immunotherapy","2025-07-15",{"date":631,"type":39},"2025-07-18",{"date":633,"type":23},"2025-07-19",{"date":635,"type":23},"2027-08-19",{"name":45,"class":46},""]